Mirjam Heemskerk
Hoogleraar Immunotherapie van kanker, in het bijzonder het ontwikkelen van celtherapie
- Naam
- Prof.dr. M.H.M. Heemskerk
- Telefoon
- +31 71 526 3207
- m.h.m.heemskerk@lumc.nl
- ORCID iD
- 0000-0001-6320-9133
Mirjam Heemskerk is hoogleraar Immunotherapie van Kanker, en hoofd van het Laboratorium voor Experimentele Hematologie van het LUMC. Zij leidt een translationele onderzoeksgroep gericht op het ontwikkelen van nieuwe cellulaire immuuntherapieën voor patiënten met kanker. In 2013 is mede onder haar leiding de eerste fase I/II TCR gen therapie studie gestart voor hematologische maligniteiten na allogene stamcel transplantatie (EudraCT number 2010-024625-20). Op dit moment worden 2 nieuwe fase I/II TCR studies binnen de afdeling Hematologie opgezet, één voor patiënten met acute myeloide leukemie (NPM1-TCR), de ander voor patiënten met multipel myeloom (BOB1-TCR). In 2011 ontving Heemskerk de Jan Swammerdam prijs voor de meest getalenteerde jonge onderzoeker vanuit de Nederlandse Vereniging voor Hematologie. Ze is penningmeester van de Nederlandse Vereniging voor Immunologie. Daarnaast is zij lid van de wetenschappelijke adviesraad van KIKA. In 2022 werd Heemskerk benoemd tot hoogleraar bij de faculteit geneeskunde met als leeropdracht “ Immuuntherapie van kanker, in het bijzonder het ontwikkelen van celtherapie”.
Meer informatie over Mirjam Heemskerk
Mirjam Heemskerk is hoogleraar Immunotherapie van Kanker, en hoofd van het Laboratorium voor Experimentele Hematologie van het LUMC. Zij leidt een translationele onderzoeksgroep gericht op het ontwikkelen van nieuwe cellulaire immuuntherapieën voor patiënten met kanker. In 2013 is mede onder haar leiding de eerste fase I/II TCR gen therapie studie gestart voor hematologische maligniteiten na allogene stamcel transplantatie (EudraCT number 2010-024625-20). Op dit moment worden 2 nieuwe fase I/II TCR studies binnen de afdeling Hematologie opgezet, één voor patiënten met acute myeloide leukemie (NPM1-TCR), de ander voor patiënten met multipel myeloom (BOB1-TCR). In 2011 ontving Heemskerk de Jan Swammerdam prijs voor de meest getalenteerde jonge onderzoeker vanuit de Nederlandse Vereniging voor Hematologie. Ze is penningmeester van de Nederlandse Vereniging voor Immunologie. Daarnaast is zij lid van de wetenschappelijke adviesraad van KIKA.
In 2022 werd Heemskerk benoemd tot hoogleraar bij de faculteit geneeskunde met als leeropdracht “ Immuuntherapie van kanker, in het bijzonder het ontwikkelen van celtherapie”.
Immuuntherapie
Bij immuuntherapie van kanker wordt het immuunsysteem van de patiënt gebruikt om de kankercellen aan te vallen. Het immuunsysteem wordt door de behandeling ondersteund of extra actief gemaakt.
Immuuntherapie waarbij patiënten worden behandeld met eigen afweercellen die in het laboratorium bewerkt zijn, laten veelbelovende resultaten zien voor patiënten met bloedcelkanker zoals leukemie en lymfklierkanker. De afweercellen worden in het laboratorium uitgerust met nieuwe herkenningsstructuren, die als een soort antenne de afweercellen helpen om de kankercellen te herkennen en te vernietigen. Deze herkenningsstructuren kunnen ofwel chimere antigeen receptoren (CAR) of T cel receptoren (TCR) zijn. Om voor elke kankertype en elke patiënt een effectieve celtherapie te kunnen ontwikkelen zijn veel kanker specifieke herkenningsstructuren noodzakelijk. Daarnaast weten we dat kankercellen kunnen ontsnappen aan enkelvoudige therapieën en is het belangrijk dat kankercellen op meerdere manieren tegelijk worden aanvallen. Mijn onderzoek richt zich op het ontwikkelen van gepersonaliseerde celtherapieën die afhankelijk van de karakteristieken van de kanker en de patiënt worden samengesteld (NWA vraag 85), een dus op maat gemaakt levend geneesmiddel.
Wetenschappelijke carrière
Mirjam Heemskerk studeerde Biomedische Wetenschappen aan de Universiteit Leiden, waar zij in 1990 afstudeerde. Haar promotie onderzoek deed zij bij de afdeling Immunologie van de Diergeneeskunde faculteit, Universiteit Utrecht. Zij promoveerde in 1995 op het proefschrift ‘Cellular immunity against murine coronaviruses; Role of MHC class II restricted cytotoxic T lymphocytes’. Van 1994 tot 1998 was zij postdoc bij de afdeling Immunologie van het Nederlands Kanker Instituut in Amsterdam waar zij zich verder specialiseerde in de humane T cel ontwikkeling en het ontwikkelen van cellulaire immuuntherapieën. In 1998 startte zij op de afdeling Hematologie van het LUMC en met behulp van een Gisela Thier Fellowship van het LUMC en verschillende KWF subsidies was zij in staat haar eigen onderzoeksgroep te starten. Vanaf 2001 is zij staflid van de afdeling Hematologie en sinds 2008 ook hoofd van het Laboratorium voor Experimentele Hematologie. In 2011 ontving zij de Jan Swammerdam Prize voor getalenteerde jonge onderzoekers van de Nederlandse Vereniging voor Hematologie. In 2022 werd Heemskerk benoemd tot hoogleraar bij de faculteit geneeskunde met als leeropdracht “ Immuuntherapie van kanker, in het bijzonder het ontwikkelen van celtherapie”. Haar oratie was in 2023 en had de titel “Levensvatbaarheid van het levend geneesmiddel”
Hoogleraar Immunotherapie van kanker, in het bijzonder het ontwikkelen van celtherapie
- Faculteit Geneeskunde
- Divisie 2
- Hematologie
- Hematologie algemeen
- (2024), Immunological differences between monophasic and biphasic synovial sarcoma with implications for immunotherapy.
- Falkenburg, J.H.F. & Heemskerk, M.H.M. (2024), TCR targeting hematopoiesis to cure leukemia, Blood 144(10): 1031-1033.
- Prins, M.L.M.; Roozen, G.V.T.; Pothast, C.R.; Huisman, W.; Binnendijk, R. van; Hartog, G. den; Kuiper, V.P.; Prins, C.; Janse, J.J.; Lamers, O.A.C.; Koopman, J.P.R.; Kruithof, A.C.; Kamerling, I.M.C.; Dijkland, R.C.; Kroon, A.C. de; Azimi, S.; Feltkamp, M.C.W.; Kuijer, M.; Jochems, S.P.; Heemskerk, M.H.M.; Rosendaal, F.R.; Roestenberg, M.; Visser, L.G. & Roukens, A.H.E. (2024), Immunogenicity and reactogenicity of intradermal mRNA-1273 SARS-CoV-2 vaccination, npj Vaccines 9(1).
- Wulp, W. van der; Luu, W.; Ressing, M.E.; Schuurman, J.; Kasteren, S.I. van; Guelen, L.; Hoeben, R.C.; Bleijlevens, B. & Heemskerk, M.H.M. (2024), Antibody-epitope conjugates deliver immunogenic T-cell epitopes more efficiently when close to cell surfaces, mAbs 16(1).
- Roozen, G.V.T.; Prins, M.L.M.; Prins, C.; Janse, J.J.; Gruyter, H.L.M.D.; Pothast, C.R.; Huisman, W.; Koopman, J.P.R.; Lamers, O.A.C.; Kuijer, M.; Myeni, S.K.; Binnendijk, R.S.V.; Hartog, G. den; Heemskerk, M.H.M.; Jochems, S.P.; Feltkamp, M.C.W.; Kikkert, M.; Rosendaal, F.R.; Roestenberg, M.; Visser, L.G. & Roukens, A.H.E. (2024), Intradermal delivery of the third dose of the mRNA-1273 SARS-CoV-2 vaccine: safety and immunogenicity of a fractional booster dose, Clinical Microbiology and Infection 30(7): 930-936.
- Voogd, L.; Drittij, A.M.H.F.; Dingenouts, C.K.E.; Franken, K.L.M.C.; Unen, V. van; Meijgaarden, K.E. van; Ruibal, P.; Hagedoorn, R.S.; Leitner, J.A.; Steinberger, P.; Heemskerk, M.H.M.; Davis, M.M.; Scriba, T.J.; Ottenhoff, T.H.M. & Joosten, S.A. (2024), MtbHLA-E-tetramer-sorted CD8+ T cells have a diverse TCR repertoire, iScience 27(3).
- Slieker, R.C.; Warmerdam, D.O.; Vermeer, M.H.; Doorn, R. van; Heemskerk, M.H.M. & Scheeren, F.A. (2024), Reassessing human MHC-I genetic diversity in T cell studies, Scientific Reports 14(1).
- Hees, E.P. van; Morton, L.T.; Remst, D.F.G.; Wouters, A.K.; Eynde, A. van den; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2024), Self-sufficient primary natural killer cells engineered to express T cell receptors and interleukin-15 exhibit improved effector function and persistence, Frontiers in Immunology 15.
- Wulp, W. van der; Gram, A.M.; Bleijlevens, B.; Hagedoorn, R.S.; Araman, C.; Kim, R.Q.; Drijfhout, J.W.; Parren, P.W.H.I.; Hibbert, R.G.; Hoeben, R.C.; Kasteren, S.I. van; Schuurman, J.; Ressing, M.E. & Heemskerk, M.H.M. (2023), Comparison of methods generating antibody-epitope conjugates for targeting cancer with virus-specific T cells, Frontiers in Immunology 14.
- Amerongen, R.A. van; Morton, L.T.; Chaudhari, U.G.; Remst, D.F.G.; Hagedoorn, R.S.; Berg, C.W. van den; Freund, C.; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2023), Human iPSC-derived preclinical models to identify toxicity of tumor-specific T cells with clinical potential, Molecular Therapy - Methods and Clinical Development 28: 249-261.
- Kroonen, J.S.; Graaf, I.J. de; Kumar, S.; Remst, D.F.G.; Wouters, A.K.; Heemskerk, M.H.M. & Vertegaal, A.C.O. (2023), Inhibition of SUMOylation enhances DNA hypomethylating drug efficacy to reduce outgrowth of hematopoietic malignancies, Leukemia 37(4): 864-876.
- Gille, I.; Hagedoorn, R.S.; Meer-prins, E.M.W. van der; Heemskerk, M.H.M. & Heidt, S. (2023), Chimeric HLA antibody receptor T cells to target HLA-specific B cells in solid organ transplantation, HLA: Immune Response Genetics 102(4).
- Sluijs, J.V. van der; Ens, D. van; Brummelman, J.; Heister, D.; Sareen, A.; Truijen, L.; Schenau, D.S.V.I.; Heemskerk, M.H.M.; Griffioen, M.; Kester, M.G.D.; Schaap, N.P.M.; Jansen, J.H.; Waart, A.B. van der; Dolstra, H. & Hobo, W. (2023), Human CD34+-derived complete plasmacytoid and conventional dendritic cell vaccine effectively induces antigen-specific CD8+T cell and NK cell responses in vitro and in vivo, Cellular and Molecular Life Sciences 80(10).
- Hofsink, Q.; Haggenburg, S.; Lissenberg-Witte, B.I.; Broers, A.E.C.; Doesum, J.A. van; Binnendijk, R.S. van; Hartog, G. den; Bhoekhan, M.S.; Haverkate, N.J.E.; Meerloo, J. van; Burger, J.A.; Bouhuijs, J.H.; Smits, G.P.; Wouters, D.; Leeuwen, E.M.M. van; Bontkes, H.J.; Kootstra, N.A.; Vogels-Nooijen, S.; Rots, N.; Beek, J. van; Heemskerk, M.H.M.; Groen, K.; Meerten, T. van; Mutsaers, P.G.N.J.; Gils, M.J. van; Goorhuis, A.; Rutten, C.E.; Hazenberg, M.D.; Nijhof, I.S. & COBRA KAI Study Team (2023), Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI) , EClinicalMedicine 61.
- Luk, S.J.; Schoppmeyer, R.; Ijsselsteijn, M.E.; Somarakis, A.; Acem, I.; Remst, D.F.G.; Cox, D.T.; Bergen, C.A.M. van; Briaire-de Bruijn, I.; Grönloh, M.L.B.; Meer, W.J. van der; Hawinkels, L.J.A.C.; Koning, R.I.; Bos, E.; Bovée, J.V.M.G.; Miranda, N.F.C.C. de; Szuhai, K.; Buul, J.D. van; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2023), VISTA Expression on Cancer-Associated Endothelium Selectively Prevents T-cell Extravasation, Cancer Immunology Research 11(11): 1480-1492.
- Pothast, C.R.; Dijk, K. van; Pool, E.S.; Halkes, C.J.M.; Heemskerk, M.H.M. & Tjon, J.M.L. (2023), SARS-CoV-2 mRNA vaccination of aplastic anemia patients is safe and effective, American Journal of Hematology 98(2): E20-E23.
- Knezevic, L.; Wachsmann, T.L.A.; Francis, O.; Dockree, T.; Bridgeman, J.S.; Wouters, A.; Wet, B. de; Cole, D.K.; Clement, M.; McLaren, J.E.; Gostick, E.; Ladell, K.; Llewellyn-Lacey, S.; Price, D.A.; Berg, H.A. van den; Tabi, Z.; Sessions, R.B.; Heemskerk, M.H.M. & Wooldridge, L. (2023), High-affinity CD8 variants enhance the sensitivity of pMHCI antigen recognition via low-affinity TCRs, Journal of Biological Chemistry 299(8): 104981.
- Wachsmann, T.L.A.; Meeuwsen, M.H.; Remst, D.F.G.; Buchner, K.; Wouters, A.K.; Hagedoorn, R.S.; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2023), Combining BCMA-targeting CAR T cells with TCR-engineered T-cell therapy to prevent immune escape of multiple myeloma, Blood Advances 7(20): 6178-6183.
- Kester, M.; Klobuch, S.; Balen, P. van; Klerk, W. de; Ru, A. de; Jedema, I.; Veelen, P. van; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2023), Forward or reversed binding of peptides within the HLA-DP peptidome is mainly determined by the HLA-DPB1 allele but with a key role for the HLA-DPA1 chain, HLA: Immune Response Genetics 101(4): 328-328.
- Pool, E.S.; Kooy-Winkelaar, Y.; Unen, V. van; Falkenburg, J.H.F.; Koning, F.; Heemskerk, M.H.M. & Tjon, J.M.L. (2023), Mass cytometric analysis unveils a disease-specific immune cell network in the bone marrow in acquired aplastic anemia, Frontiers in Immunology 14.
- Rooij, M.A.J. de; Remst, D.F.G.; Steen, D.M. van der; Wouters, A.K.; Hagedoorn, R.S.; Kester, M.G.D.; Meeuwsen, M.H.; Wachsmann, T.L.A.; Ru, A.H. de; Veelen, P.A. van; Verdegaal, E.M.E.; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2023), A library of cancer testis specific T cell receptors for T cell receptor gene therapy, Molecular Therapy - Oncolytics 28.
- Amerongen, R.A. van; Tuit, S.; Wouters, A.K.; Meent, M. van de; Siekman, S.L.; Meeuwsen, M.H.; Wachsmann, T.L.A.; Remst, D.F.G.; Hagedoorn, R.S.; Steen, D.M. van der; Ru, A.H. de; Verdegaal, E.M.E.; Veelen, P.A. van; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2023), PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer, Frontiers in Immunology 14.
- Meeuwsen, M.H.; Wouters, A.K.; Wachsmann, T.L.A.; Hagedoorn, R.S.; Kester, M.G.D.; Remst, D.F.G.; Steen, D.M. van der; Ru, A.H. de; Hees, E.P. van; Kremer, M.; Griffioen, M.; Veelen, P.A. van; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2023), Broadly applicable TCR-based therapy for multiple myeloma targeting the immunoglobulin J chain, Journal of Hematology and Oncology 16(1).
- Gelmi, M.C.; Gezgin, G.; Velden, P.A. van der; Luyten, G.P.M.; Luk, S.J.; Heemskerk, M.H.M. & Jager, M.J. (2023), PRAME Expression: A Target for Cancer Immunotherapy and a Prognostic Factor in Uveal Melanoma, Investigative Ophthalmology & Visual Science 64(15).
- Wulp, W. van der; Remst, D.F.G.; Kester, M.G.D.; Hagedoorn, R.S.; Parren, P.W.H.I.; Kasteren, S.I. van; Schuurman, J.; Hoeben, R.C.; Ressing, M.E.; Bleijlevens, B. & Heemskerk, M.H.M. (2023), Antibody-mediated delivery of viral epitopes to redirect EBV-specific CD8+ T-cell immunity towards cancer cells, Cancer Gene Therapy 31.
- Haggenburg, S.; Hofsink, Q.; Lissenberg-Witte, B.I.; Broers, A.E.C.; Doesum, J.A. van; Binnendijk, R.S. van; Hartog, G. den; Bhoekhan, M.S.; Haverkate, N.J.E.; Burger, J.A.; Bouhuijs, J.H.; Smits, G.P.; Wouters, D.; Leeuwen, E.M.M. van; Bontkes, H.J.; Kootstra, N.A.; Zweegman, S.; Kater, A.P.; Heemskerk, M.H.M.; Groen, K.; Meerten, T. van; Mutsaers, P.G.N.J.; Beaumont, T.; Gils, M.J. van; Goorhuis, A.; Rutten, C.E.; Hazenberg, M.D.; Nijhof, I.S. & Cobra Kai Study Team (2022), Antibody response in immunocompromised patients with hematologic cancers who received a 3-dose mRNA-1273 vaccination schedule for COVID-19, JAMA Oncology 8(10): 1477-1483.
- Gille, I.; Vergunst, M.; Meer-Prins, E. van der; Heidt, S.; Gille, I.; Hagedoorn, R. & Heemskerk, M. (2022), CHIMERIC HLA-ANTIGEN RECEPTOR (CHAR) T-CELL ENGINEERING-A NEW APPROACH TO TARGET HLA SENSITIZATION, Human Immunology 83: 26-26.
- Pothast, C.R.; Hofsink, Q.; Haggenburg, S.; Michel, B.S.; Haverkate, N.J.E.; Dijkland, R.C.; Dijk, K. van; Falkenburg, F.J.H.; Broers, A.E.C.; Doesum, J. van; Binnendijk, R.S. van; Hartog, G. den; Burger, J.A.; Bouhuijs, J.H.; Lissenberg-Witte, B.I.; Smits, G.P.; Wouters, D.; Leeuwen, E.M.M. van; Bontkes, H.J.; Kootstra, N.A.; Zweegman, S.; Kater, A.P.; Groen, K.; Meerten, T. van; Mutsaers, P.G.N.J.; Beaumont, T.; Gils, M.J. van; Goorhuis, A.; Hazenberg, M.D.; Nijhof, I.S.; Heemskerk, M.H.M. & Rutten, C.E. (2022), Discordant Cellular and Humoral Responses to a 3-Dose COVID-19 mRNA Vaccination Schedule in Patients with Hematologic Malignancies, Blood 140: 8347-8349.
- Pothast, C.R.; Hofsink, Q.; Haggenburg, S.; Bhoekhan, M.; Haverkate, N.J.E.; Dijkland, R.C.; Dijk, K. van; Falkenburg, F.J.H.; Broers, A.E.C.; Doesum, J. van; Binnendijk, R.S. van; Hartog, G. den; Burger, J.A.; Bouhuijs, J.H.; Lissenberg-Witte, B.I.; Smits, G.P.; Wouters, D.; Leeuwen, E.M.M. van; Bontkes, H.J.; Kootstra, N.A.; Zweegman, S.; Kater, A.P.; Groen, K.; Meerten, T. van; Mutsaers, P.G.N.J.; Beaumont, T.; Gils, M.J. van; Goorhuis, A.; Hazenberg, M.D.; Nijhof, I.S.; Heemskerk, M.H.M. & Rutten, C.E. (2022), Sickle Cell Disease Patients Mount Adequate Humoral but Reduced Cellular Responses to COVID-19 Vaccination, Blood 140: 1957-1959.
- Boerenkamp, L.S.; Pothast, C.R.; Dijkland, R.C.; Dijk, K. van; Gorkom, G.N.Y. van; Loo, I.H.M. van; Wieten, L.; Halkes, C.J.M.; Heemskerk, M.H.M. & Elssen, C.H.M.J. van (2022), Increased CD8 T-cell immunity after COVID-19 vaccination in lymphoid malignancy patients lacking adequate humoral response: An immune compensation mechanism?
- Haggenburg, S.; Lissenberg-Witte, B.I.; Binnendijk, R.S. van; Hartog, G. den; Bhoekhan, M.S.; Haverkate, N.J.E.; Rooij, D.M. de; Meerloo, J. van; Cloos, J.; Kootstra, N.A.; Wouters, D.; Weijers, S.S.; Leeuwen, E.M.M. van; Bontkes, H.J.; Tonouh-Aajoud, S.; Heemskerk, M.H.M.; Sanders, R.W.; Roelandse-Koop, E.; Hofsink, Q.; Groen, K.; Cetinel, L.; Schellekens, L.; Hartog, Y.M. den; Toussaint, B.; Kant, I.M.J.; Graas, T.; Pater, E. de; Dik, W.A.; Engel, M.D.; Pierie, C.R.N.; Janssen, S.R.; Dijkman, E. van; Poniman, M.; Burger, J.A.; Bouhuijs, J.H.; Smits, G.; Rots, N.Y.; Zweegman, S.; Kater, A.P.; Meerten, T. van; Mutsaers, P.G.N.J.; Doesum, J.A. van; Broers, A.E.C.; Gils, M.J. van; Goorhuis, A.; Rutten, C.E.; Hazenberg, M.D. & Nijhof, I.S. (2022), Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients, Blood Advances 6(5): 1537-1546.
- Gille, I.; Claas, F.H.J.; Haasnoot, G.W.; Heemskerk, M.H.M. & Heidt, S. (2022), Chimeric Antigen Receptor (CAR) Regulatory T-Cells in Solid Organ Transplantation, Frontiers in Immunology 13.
- Pothast, C.R.; Dijkland, R.C.; Thaler, M.; Hagedoorn, R.S.; Kester, M.G.D.; Wouters, A.K.; Hiemstra, P.S.; Hemert, M.J. van; Gras, S.; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2022), Sars-Cov-2-Specific CD4+ and CD8+ T Cell Responses Can Originate from Cross-Reactive CMV-Specific T Cells, Blood 140: 2631-2632.
- Meeuwsen, M.H.; Wouters, A.K.; Hagedoorn, R.S.; Kester, M.G.D.; Remst, D.F.G.; Steen, D.M. van der; Ru, A. de; Veelen, P.A. van; Rossjohn, J.; Gras, S.; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2022), Cutting edge, The Journal of Immunology 208(8): 1851-1856.
- Pothast, C.R.; Dijkland, R.C.; Thaler, M.; Hagedoorn, R.S.; Kester, M.G.D.; Wouters, A.K.; Hiemstra, P.S.; Hemert, M.J. van; Gras, S.; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2022), SARS-CoV-2-specific CD4+ and CD8+ T cell responses can originate from cross- reactive CMV- specific T cells, eLife 11.
- Morton, L.T.; Wachsmann, T.L.A.; Meeuwsen, M.H.; Wouters, A.K.; Remst, D.F.G.; Loenen, M.M. van; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2022), T cell receptor engineering of primary NK cells to therapeutically target tumors and tumor immune evasion, Journal for ImmunoTherapy of Cancer 10(3).
- Roukens, A.H.E.; Pothast, C.R.; Konig, M.; Huisman, W.; Dalebout, T.; Tak, T.; Azimi, S.; Kruize, Y.; Hagedoorn, R.S.; Zlei, M.; Staal, F.J.T.; Bie, F.J. de; Dongen, J.J.M. van; Arbous, S.M.; Zhang, J.L.H.; Verheij, M.; Prins, C.; Does, A.M. van der; Hiemstra, P.S.; Vries, J.J.C. de; Janse, J.J.; Roestenberg, M.; Myeni, S.K.; Kikkert, M.; Yazdanbakhsh, M.; Heemskerk, M.H.M.; Smits, H.H.; Jochems, S.P.; Collaboration BEAT-COVID Grp & Collaboration COVID-19 LUMC Grp (2022), Prolonged activation of nasal immune cell populations and development of tissue-resident SARS-CoV-2-specific CD8(+) T cell responses following COVID-19, Nature Immunology 23.
- Anadon, C.M.; Yu, X.Q.; Hanggi, K.; Biswas, S.; Chaurio, R.A.; Martin, A.; Payne, K.K.; Mandal, G.; Innamarato, P.; Harro, C.M.; Mine, J.A.; Sprenger, K.B.; Cortina, C.; Powers, J.J.; Costich, T.L.; Perez, B.A.; Gatenbee, C.D.; Prabhakaran, S.; Marchion, D.; Heemskerk, M.H.M.; Curiel, T.J.; Anderson, A.R.; Wenham, R.M.; Rodriguez, P.C. & Conejo-Garcia, J.R. (2022), Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T cells, Cancer Cell 40(5): 545-+.
- Zlei, M.; Sidorov, I.A.; Joosten, S.A.; Heemskerk, M.H.M.; Myeni, S.K.; Pothast, C.R.; Brouwer, C.S. de; Boomaars-van der Zanden, A.L.; Meijgaarden, K.E. van; Morales, S.T.; Wessels, E.; Janse, J.J.; Goeman, J.J.; Cobbaert, C.M.; Kroes, A.C.M.; Cannegieter, S.C.; Roestenberg, M.; Visser, L.G.; Kikkert, M.; Feltkamp, M.C.W.; Arbous, S.M.; Staal, F.J.T.; Ottenhoff, T.H.M.; Dongen, J.J.M. van; Roukens, A.H.E.; Vries, J.J.C. de; Collaboration BEAT-COVID & Collaboration LUMC COVID (2022), Immune determinants of viral clearance in hospitalised COVID-19 patients, Cells 11(17).
- Huisman, W.; Gille, I.; Maarel, L.E. van der; Hageman, L.; Morton, L.T.; Jong, R.C.M. de; Heemskerk, M.H.M.; Amsen, D.; Falkenburg, J.H.F. & Jedema, I. (2022), Identification of functional HLA-A*01:01-restricted Epstein-Barr latent membrane protein 2-Specific T-Cell receptors, The Journal of Infectious Diseases 226(5): 833-842.
- Gille, I.; Hagedoorn, R.S.; Vergunst, M.; Heemskerk, M.H.M. & Heidt, S. (2022), Chimeric HLA-antigen receptor (CHAR) T-cell development: A new approach to target HLA sensitization, HLA: Immune Response Genetics 99(5): 418-418.
- Wachsmann, T.L.A.; Wouters, A.K.; Remst, D.F.G.; Hagedoorn, R.S.; Meeuwsen, M.H.; Diest, E. van; Leusen, J.; Kuball, J.; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2022), Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure, OncoImmunology 11(1).
- Meeuwsen, M.H.; Wouters, A.K.; Jahn, L.; Hagedoorn, R.S.; Kester, M.G.D.; Remst, D.F.G.; Morton, L.T.; Steen, D.M. van der; Kweekel, C.; Ru, A.H. de; Griffioen, M.; Veelen, P.A. van; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2022), A broad and systematic approach to identify B cell malignancy-targeting TCRs for multi-antigen-based T cell therapy, Molecular Therapy 30(2): 564-578.
- Noordenbos, T.; Groot, F.A. de; Groen, R.A.L. de; Haan, L.M. de; Krog, R.T.; Sijs-Szabo, A.; Griffioen, M.; Groot, R. de; Heemskerk, M.H.M.; Ijsselsteijn, M.E.; Terpstra, V.; Nijland, M.; Mutseaers, P.; Chamuleau, M.E.D.; Kersten, M.J.; Diepstra, A.; Bovee, J.; Jansen, P.M.; Miranda, N.F.C.C. de & Vermaat, J.S.P. (2022), Special Anatomical Subtypes of Diffuse Large B-Cell Lymphoma Have Distinct Tumor Microenvironments, Blood 140.
- Pool, E.S.; Kooy-Winkelaar, Y.; Unen, V. van; Falkenburg, J.H.F.; Koning, F.; Heemskerk, M.H.M. & Tjon, J.M.L. (2022), High-Dimensional Mass Cytometric Analysis of the Bone Marrow Compartment Identifies a Disease-Specific Immune Cell Network in Aplastic Anemia, Blood 140.
- Struckman, N.E.; Klobuch, S.; Kester, M.G.D.; Klerk, W. de; Ru, A.H. de; Heemskerk, M.H.M.; Veelen, P.A. van; Balen, P. van; Falkenburg, J.H.F. & Griffioen, M. (2022), Immunotherapy By Targeting CD45 in Mismatched HLA-DP to Treat Patients after Allogeneic Stem Cell Transplantation, Blood 140: 4545-4546.
- Klobuch, S, Heemskerk, MHM, Falkenburg, JHF, Balen, P van, Pothast & CR (2022), Human T cells recognize HLA-DP bound peptides in two orientations, Proceedings of the National Academy of Sciences of the United States of America 119(49).
- Amerongen, R.A. van; Hagedoorn, R.S.; Remst, D.F.G.; Assendelft, D.C.; Steen, D.M. van der; Wouters, A.K.; Meent, M. van de; Kester, M.G.D.; Ru, A.H. de; Griffioen, M.; Veelen, P.A. van; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2022), WT1-specific TCRs directed against newly identified peptides install antitumor reactivity against acute myeloid leukemia and ovarian carcinoma, Journal for ImmunoTherapy of Cancer 10(6).
- Meeuwsen, M.H.; Wouters, A.K.; Wachsmann, T.L.A.; Hagedoorn, R.S.; Kester, M.G.D.; Remst, D.F.G.; Steen, D.M. van der; Ru, A.H. de; Hees, E.P. van; Griffioen, M.; Veelen, P.A. van; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2022), Broadly Applicable TCR Based Therapy for Multiple Myeloma Targeting the Jchain, Blood 140: 4498-4499.
- Meeuwsen, M.H.; Wouters, A.K.; Wachsmann, T.L.A.; Hagedoorn, R.S.; Remst, D.F.G.; Kester, M.G.D.; Steen, D.M. van der; Ru, A.H. de; Veelen, P.A. van; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2022), T Cell Receptor-Based Targeting of Immunoglobulin Constant Domains for Treatment of Multiple Myeloma, Blood 140: 10292-10293.
- Koutsoumpli, G.; Lee, D.I. van der; Groenland, N.C.; Honders, M.W.; Jong, R.C.M. de; Hagedoorn, R.S.; Veelken, H.; Veelen, P.A. van; Lock, D.; Heemskerk, M.H.M.; Falkenburg, J.H.F.; Johnston, I. & Griffioen, M. (2022), Immunotherapy Targeting Mutant Nucleophosmin-1 on Acute Myeloid Leukemia, Blood 140: 10243-10244.
- Verkerk, T.; Waard, A.A. de; Hoefakker, K.; Steen, D.M. van der; Jongsma, M.L.M.; Kadosh, D.M.; Bliss, S.; Ru, A.H. de; Admon, A.; Veelen, P.A. van; Griffioen, M.; Heemskerk, M.H.M. & Spaapen, R.M. (2021), Healthy cells functionally present TAP-independent SSR1 peptides: implications for selection of clinically relevant antigens, European Journal of Immunology 51: 223-223.
- Sluijs, J.V.E. van der; Ens, D. van; Heister, D.; Brummelman, J.; Sareen, A.; Waart, A. van der; Schaap, N.; Kester, M.; Griffioen, M.; Heemskerk, M.; Jansen, J.; Dolstra, H. & Hobo, W. (2021), High-dimensional flow-cytometry and functional evaluation reveals enhanced potency of stem cell-derived dendritic cell bulk vaccination to boost T cell immunity, European Journal of Immunology 51: 49-49.
- Schmidt, N.M.; Wing, P.A.C.; Diniz, M.O.; Pallett, L.J.; Swadling, L.; Harris, J.M.; Burton, A.R.; Jeffery-Smith, A.; Zakeri, N.; Amin, O.E.; Kucykowicz, S.; Heemskerk, M.H.; Davidson, B.; Meyer, T.; Grove, J.; Stauss, H.J.; Pineda-Torra, I.; Jolly, C.; Jury, E.C.; McKeating, J.A. & Maini, M.K. (2021), Targeting human acyl-CoA:cholesterol acyltransferase as a dual viral and T cell metabolic checkpoint, Nature Communications 12(1).
- Jongsma, M.L.M.; Waard, A.A. de; Raaben, M.; Zhang, T.; Cabukusta, B.; Platzer, R.; Blomen, V.A.; Xagara, A.; Verkerk, T.; Bliss, S.; Kong, X.R.; Gerke, C.; Janssen, L.; Stickel, E.; Holst, S.; Plomp, R.; Mulder, A.; Ferrone, S.; Claas, F.H.J.; Heemskerk, M.H.M.; Griffioen, M.; Halenius, A.; Overkleeft, H.; Huppa, J.B.; Wuhrer, M.; Brummelkamp, T.R.; Neefjes, J. & Spaapen, R.M. (2021), The SPPL3-defined glycosphingolipid repertoire orchestrates HLA class I-mediated immune responses (vol 54, 132.e1, 2021), Immunity 54(2): 387-387.
- Sluijs, J.V. van der; Ens, D. van; Thordardottir, S.; Vodegel, D.; Hermens, I.; Waart, A.B. van der; Falkenburg, J.H.F.; Kester, M.G.D.; Rink, I. de; Heemskerk, M.H.M.; Borst, J.; Schaap, N.P.M.; Jansen, J.H.; Xiao, Y.L.; Dolstra, H. & Hobo, W. (2021), Clinically applicable CD34(+)-derived blood dendritic cell subsets exhibit key subset-specific features and potently boost anti-tumor T and NK cell responses, Cancer Immunology, Immunotherapy 70.
- Lee, D.I. van der; Koutsoumpli, G.; Reijmers, R.M.; Honders, M.W.; Jong, R.C.M. de; Remst, D.F.G.; Wachsmann, T.L.A.; Hagedoorn, R.S.; Franken, K.L.M.C.; Kester, M.G.D.; Harber, K.J.; Roelofsen, L.M.; Schouten, A.M.; Mulder, A.; Drijfhout, J.W.; Veelken, H.; Veelen, P.A. van; Heemskerk, M.H.M.; Falkenburg, J.H.F. & Griffioen, M. (2021), An HLA-A*11:01-binding neoantigen from mutated NPM1 as target for TCR gene therapy in AML, Cancers 13(21).
- Waard, A.A. de; Verkerk, T.; Hoefakker, K.; Steen, D.M. van der; Jongsma, M.L.M.; Kadosh, D.M.; Bliss, S.; Ru, A.H. de; Admon, A.; Veelen, P.A. van; Griffioen, M.; Heemskerk, M.H.M. & Spaapen, R.M. (2021), Healthy cells functionally present TAP-independent SSR1 peptides, iScience 24(2).
- Hanssen, J.L.J.; Stienstra, J.; Boers, S.A.; Pothast, C.R.; Zaaijer, H.L.; Tjon, J.M.; Heemskerk, M.H.M.; Feltkamp, M.C.W. & Arend, S.M. (2021), Convalescent plasma in a patient with protracted COVID-19 and secondary hypogammaglobulinemia due to chronic lymphocytic leukemia, Infectious Disease Reports 13(4): 855--864.
- Rooij, M.A.J. de; Steen, D.M.; Remst, D.; Wouters, A.; Kester, M.G.D.; Hagedoorn, R.S.; Veelen, P.A. van; Verdegaal, E.M.E.; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2021), A library of novel cancer testis specific T-cell receptors for T-cell receptor gene therapy, Journal for ImmunoTherapy of Cancer 9: A2-A3.
- Jongsma, M.L.M.; Waard, A.A. de; Raaben, M.; Zhang, T.; Cabukusta, B.; Platzer, R.; Blomen, V.A.; Xagara, A.; Verkerk, T.; Bliss, S.; Kong, X.R.; Gerke, C.; Janssen, L.; Stickel, E.; Holst, S.; Plomp, R.; Mulder, A.; Ferrone, S.; Claas, F.H.J.; Heemskerk, M.H.M.; Griffioen, M.; Halenius, A.; Overkleeft, H.; Huppa, J.B.; Wuhrer, M.; Brummelkamp, T.R.; Neefjes, J. & Spaapen, R.M. (2021), The SPPL3-defined glycosphingolipid repertoire orchestrates HLA class I-mediated immune responses, Immunity 54(1): 132-+.
- Lichtenegger, F.S.; Schnorfeil, F.M.; Rothe, M.; Deiser, K.; Altmann, T.; Bucklein, V.L.; Kohnke, T.; Augsberger, C.; Konstandin, N.P.; Spiekermann, K.; Moosmann, A.; Boehm, S.; Boxberg, M.; Heemskerk, M.H.M.; Goerlich, D.; Wittmann, G.; Wagner, B.; Hiddemann, W.; Schendel, D.J.; Kvalheim, G.; Bigalke, I. & Subklewe, M. (2020), Toll-like receptor 7/8-matured RNA-transduced dendritic cells as post-remission therapy in acute myeloid leukaemia, Clinical & Translational Immunology 9(3).
- Morton, L.T.; Reijmers, R.M.; Wouters, A.K.; Kweekel, C.; Remst, D.F.G.; Pothast, C.R.; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2020), Simultaneous deletion of endogenous TCR alpha beta for TCR gene therapy creates an improved and safe cellular therapeutic, Molecular Therapy 28(1): 64-74.
- Balen, P. van; Kester, M.G.D.; Klerk, W. de; Crivello, P.; Arrieta-Bolanos, E.; Ru, A.H. de; Jedema, I.; Mohammed, Y.; Heemskerk, M.H.M.; Fleischhauer, K.; Veelen, P.A. van & Falkenburg, J.H.F. (2020), Immunopeptidome analysis of HLA-DPB1 allelic variants reveals new functional hierarchies, The Journal of Immunology 204(12): 3273-3282.
- Ruibal, P.; Franken, K.L.M.C.; Meijgaarden, K.E. van; Loon, J.J.F. van; Steen, D. van der; Heemskerk, M.H.M.; Ottenhoff, T.H.M. & Joosten, S.A. (2020), Peptide binding to HLA-E molecules in humans, nonhuman primates, and mice reveals unique binding peptides but remarkably conserved anchor residues, The Journal of Immunology 205(10): 2861-2872.
- Rooij, M.A.J. de; Steen, D.M. van der; Remst, D.; Wouters, A.; Meent, M. van der; Hagedoorn, R.S.; Kester, M.G.D.; Veelen, P.A. van; Falkenburg, F.J.H. & Heemskerk, M.H.M. (2020), High-affinity TCRS specific for cancer testis antigens as a therapy for multiple myeloma and solid tumors, Journal for ImmunoTherapy of Cancer 8: A49-A49.
- Balen, P. van; Jedema, I.; Loenen, M.M. van; Boer, R. de; Egmond, H.M. van; Hagedoorn, R.S.; Hoogstaten, C.; Veld, S.A.J.; Hageman, L.; Liempt, P.A.G. van; Zwaginga, J.J.; Meij, P.; Veelken, H.; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2020), HA-1H T-cell receptor gene transfer to redirect virus-specific T cells for treatment of hematological malignancies after allogeneic stem cell transplantation, Frontiers in Immunology 11.
- Morton, L.T.; Wouters, A.K.; Remst, D.F.; Hagedoorn, R.S.; Loenen, M.M. van; Boer, R. de; Falkenberg, J.H.F. & Heemskerk, M.H.M. (2019), Effective rerouting of NK cell cytotoxicity against B-cell malignancies upon TCR gene transfer, Cancer Immunology Research 7(2).
- Lee, D.I. van der; Reijmers, R.M.; Honders, M.W.; Hagedoorn, R.S.; Jong, R.C.M. de; Kester, M.G.D.; Steen, D.M. van der; Ru, A.H. de; Kweekel, C.; Bijen, H.M.; Jedema, I.; Veelken, H.; Veelen, P.A. van; Heemskerk, M.H.M.; Falkenburg, J.H.F. & Griffioen, M. (2019), Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia, Journal of Clinical Investigation 129(2): 774-785.
- Lee, D.I. van der; Reijmers, R.M.; Honders, M.W.; Hagedoorn, R.S.; Jong, R.M. de; Kester, M.G.D.; Steen, D.M. van der; Ru, A.H. de; Kweekel, C.; Jedema, I.; Veelken, H.; Heemskerk, M.M.; Veelen, P.A. van; Falkenburg, J.H.F. & Griffioen, M. (2019), Mutated NPM1 as target for immunotherapy of acute myeloid leukemia, Cancer Immunology Research 7(2).
- Thomas, S.; Mohammed, F.; Reijmers, R.M.; Woolston, A.; Stauss, T.; Kennedy, A.; Stirling, D.; Holler, A.; Green, L.; Jones, D.; Matthews, K.K.; Price, D.A.; Chain, B.M.; Heemskerk, M.H.M.; Morris, E.C.; Willcox, B.E. & Stauss, H.J. (2019), Framework engineering to produce dominant T cell receptors with enhanced antigen-specific function, Nature Communications 10.
- Krijgsman, D.; Vries, N.L. de; Skovbo, A.; Andersen, M.N.; Swets, M.; Bastiaannet, E.; Vahrmeijer, A.L.; Velde, C.J.H. van de; Heemskerk, M.H.M.; Hokland, M. & Kuppen, P.J.K. (2019), Characterization of circulating T-, NK-, and NKT cell subsets in patients with colorectal cancer: the peripheral blood immune cell profile, Cancer Immunology, Immunotherapy 68(6): 1011-1024.
- Pascutti, M.F.; Geerman, S.; Collins, N.; Brasser, G.; Nota, B.; Stark, R.; Behr, F.; Oja, A.; Slot, E.; Panagioti, E.; Prier, J.E.; Hickson, S.; Wolkers, M.C.; Heemskerk, M.H.M.; Hombrink, P.; Arens, R.; Mackay, L.K.; Gisbergen, K.P.J.M. van & Nolte, M.A. (2019), Peripheral and systemic antigens elicit an expandable pool of resident memory CD8(+) T cells in the bone marrow, European Journal of Immunology 49(6): 853-872.
- Mari, L.; Hoefnagel, S.J.M.; Zito, D.; Meent, M. van de; Endert, P. van; Calpe, S.; Serra, M.D.S.; Heemskerk, M.H.M.; Laarhoven, H.W.M. van; Hulshof, M.C.C.M.; Gisbertz, S.S.; Medema, J.P.; Henegouwen, M.I.V.; Meijer, S.L.; Bergman, J.J.G.H.M.; Milano, F. & Krishnadath, K.K. (2018), microRNA 125a Regulates MHC-I Expression on Esophageal Adenocarcinoma Cells, Associated With Suppression of Antitumor Immune Response and Poor Outcomes of Patients, Gastroenterology 155(3): 784-798.
- Bijen, H.M.; Steen, D.M. van der; Hagedoorn, R.S.; Wouters, A.K.; Wooldridge, L.; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2018), Preclinical Strategies to Identify Off-Target Toxicity of High-Affinity TCRs, Molecular Therapy 26(5): 1206-1214.
- (2018), A jurkat 76 based triple parameter reporter system to evaluate TCR functions and adoptive T cell strategies, Oncotarget 9.
- Cao, J.F.; Brouwer, N.J.; Jordanova, E.S.; Marinkovic, M.; Duinen, S.G. van; Waard, N.E. de; Ksander, B.R.; Mulder, A.; Claas, F.H.J.; Heemskerk, M.H.M. & Jager, M.J. (2018), HLA Class I Antigen Expression in Conjunctival Melanoma Is Not Associated With PD-L1/PD-1 Status, Investigative Ophthalmology & Visual Science 59(2): 1005-1015.
- Bijen, H.M.; Hassan, C.; Kester, M.G.D.; Janssen, G.M.C.; Hombrink, P.; Ru, A.H. de; Drijfhout, J.W.; Meiring, H.D.; Jong, A.P. de; Falkenburg, J.H.F.; Jimenez, C.R.; Heemskerk, M.H.M. & Veelen, P.A. van (2018), Specific TCell Responses against Minor Histocompatibility Antigens Cannot Generally Be Explained by Absence of Their Allelic Counterparts on the Cell Surface, Proteomics 18(12).
- Marijt, K.A.; Blijleven, L.; Verdegaal, E.M.E.; Kester, M.G.; Kowalewski, D.J.; Rammensee, H.G.; Stevanovic, S.; Heemskerk, M.H.M.; Burg, S.H. van der & Hall, T. van (2018), Identification of non-mutated neoantigens presented by TAP-deficient tumors, Journal of Experimental Medicine 215(9): 2325-2337.
- Orlando, D.; Miele, E.; Angelis, B. de; Guercio, M.; Boffa, I.; Sinibaldi, M.; Po, A.; Caruana, I.; Abballe, L.; Carai, A.; Caruso, S.; Camera, A.; Moseleys, A.; Hagedoorn, R.S.; Heemskerk, M.H.M.; Giangaspero, F.; Mastronuzzi, A.; Ferretti, E.; Locatelli, F. & Quintarelli, C. (2018), Adoptive Immunotherapy Using PRAME-Specific T Cells in Medulloblastoma, Cancer Research 78(12): 3337-3349.
- Luk, S.J.; Steen, D.M. van der; Hagedoorn, R.S.; Jordanova, E.S.; Schilham, M.W.; Bovee, J.V.M.G.; Cleven, A.H.G.; Falkenburg, J.H.F.; Szuhai, K. & Heemskerk, M.H.M. (2018), PRAME and HLA Class I expression patterns make synovial sarcoma a suitable target for PRAME specific T-cell receptor gene therapy, OncoImmunology 7(12).
- Jahn, L.; Hombrink, P.; Hagedoorn, R.S.; Kester, M.G.D.; Steen, D.M. van der; Rodriguez, T.; Pentcheva-Hoang, T.; Ru, A.H.; Schoonakker, M.P.; Meeuwsen, M.H.; Griffioen, M.; Veelen, P.A. van; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2017), TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1, Blood 129(10): 1284-1295.
- Gezgin, G.; Luk, S.J.; Cao, J.F.; Dogrusoz, M.; Steen, D.M. van der; Hagedoorn, R.S.; Krijgsman, D.; Velden, P.A. van der; Field, M.G.; Luyten, G.P.M.; Szuhai, K.; Harbour, J.W.; Jordanova, E.S.; Heemskerk, M.H.M. & Jager, M.J. (2017), PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma, JAMA Ophthalmology 135(6).
- Jolink, H.; Boer, R. de; Hombrink, P.; Jonkers, R.E.; Dissel, J.T. van; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2017), Pulmonary immune responses against Aspergillus fumigatus are characterized by high frequencies of IL-17 producing T-cells, Journal of Infection 74(1): 81-88.
- Jahn, L. & Heemskerk, M.H.M. (2017), Detection of clinically relevant T-cell receptors requires tailored approaches, and TCR gene therapy carries inherent risks, Translational cancer research 6: S1118-S1120.
- Bergen, C.A.M. van; Luxemburg-Heijs, S.A.P. van; Wreede, L.C. de; Eefting, M.; Borne, P.A. von dem; Balen, P. van; Heemskerk, M.H.M.; Mulder, A.; Claas, F.H.J.; Navarrete, M.A.; Honders, W.M.; Rutten, C.E.; Veelken, H.; Jedema, I.; Halkes, C.J.M.; Griffioen, M. & Falkenburg, J.H.F. (2017), Selective graft-versus-leukemia depends on magnitude and diversity of the alloreactive T cell response, Journal of Clinical Investigation 127(2): 517-529.
- Orlando, D.; Angelis, B. de; Caruana, I.; Guercio, M.; Boffa, I.; Mastronuzzi, A.; Miele, E.; Ferretti, E.; Moseley, A.; Hagedoorn, R.; Boer, R. de; Heemskerk, M.H.; Locatelli, F. & Quintarelli, C. (2016), Adoptive cell immunotherapy in medulloblastoma based on T cells redirected toward tumor cells by PRAME specific αβTCR gene modification, Bone Marrow Transplantation 51: S312-S312.
- Pentcheva-Hoang, T.; Torres, D.; Rodriguez, T.; Korngold, A.; Lu, A.; Crisostomo, J.; Moseley, A.; Jahn, L.; Heemskerk, M.H.M.; Slawin, K.; Spencer, D. & Foster, A. (2016), GoTCR: Inducible MyD88/CD40 (iMC) enhances proliferation and survival of tumor-specific TCR-modified T cells and improves antitumor efficacy in myeloma, Cancer Immunology Research 4(11).
- Deiser, K.; Lichtenegger, F.; Schnorfeil, F.; Köhnke, T.; Altmann, T.; Bücklein, V.; Moosmann, A.; Brüggemann, M.; Heemskerk, M.H.M.; Wagner, B.; Hiddemann, W.; Bigalke, I.; Kvalheim, G. & Subklewe, M. (2016), Next-generation dendritic cell vaccination in postremission therapy of AML: Results of a clinical phase I/II trial, European Journal of Cancer 55: S22-S23.
- Bergen, C.A.M. van; Steen, D.M. van der; Kester, M.G.D.; Koning, M.T.; Veelen, P.A. van; Griffioen, M.; Falkenburg, J.H.F.; Heemskerk, M.H.M.; Veelken, H. & Navarrete, M.A. (2016), Endogenous Immunoglobulin-Derived Neoepitopes Are Processed and Form a Sizeable Fraction of the HLA Class I Ligandome of Human Lymphoma Cells, Blood 128(22).
- Gram, A.M.; Oosenbrug, T.; Lindenbergh, M.F.S.; Bull, C.; Comvalius, A.; Dickson, K.J.I.; Wiegant, J.; Vrolijk, H.; Lebbink, R.J.; Wolterbeek, R.; Adema, G.J.; Griffioen, M.; Heemskerk, M.H.M.; Tscharke, D.C.; Hutt-Fletcher, L.M.; Wiertz, E.J.H.J.; Hoeben, R.C. & Ressing, M.E. (2016), The Epstein-Barr Virus Glycoprotein gp150 Forms an Immune-Evasive Glycan Shield at the Surface of Infected Cells, PLoS Pathogens 12(4).
- Caruana, I.; Orlando, D.; Angelis, B. de; Boffa, I.; Guercio, M.; Carai, A.; Massimi, L.; Ferretti, E.; Miele, E.; Po, A.; Moseley, A.; Hagedoorn, R.S.; Boer, R. de; Falkenburg, J.H.F.; Heemskerk, M.H.M.; Locatelli, F.; Mastronuzzi, A. & Quintarelli, C. (2016), ADOPTIVE CELL IMMUNOTHERAPY IN MEDULLOBLASTOMA BASED ON T CELLS REDIRECTED TOWARD TUMOR CELLS BY PRAME SPECIFIC alpha beta TCR GENE MODIFICATION, Neuro-Oncology 18: 111-111.
- Hobo, W.; Hutten, T.; Thordardottir, S.; Fredrix, H.; Janssen, L.; Woestenenk, R.; Tel, J.; Joosten, B.; Cambi, A.; Heemskerk, M.; Franssen, G.; Boerman, O.; Bakker, A.; Jansen, J.; Schaap, N. & Dolstra, H. (2016), CLEC12A-mediated antigen uptake and cross-presentation by human dendritic cell subsets efficiently boosts tumor-reactive T cells, Bone Marrow Transplantation 51: S323-S324.
- Breman, E.; Ruben, J.M.; Franken, K.L.; Heemskerk, M.H.M.; Roelen, D.L.; Claas, F.H. & Kooten, C. van (2016), Uptake of HLA Alloantigens via CD89 and CD206 Does Not Enhance Antigen Presentation by Indirect Allorecognition, Journal of Immunology Research.
- Jahn, L.; Steen, D.M. van der; Hagedoorn, R.S.; Hombrink, P.; Kester, M.G.D.; Schoonakker, M.P.; Ridder, D. de; Veelen, P.A. van; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2016), Generation of CD20-specific TCRs for TCR gene therapy of CD20(low) B-cell malignancies insusceptible to CD20-targeting antibodies, Oncotarget 7(47): 77021-77037.
- Hutten, T.J.A.; Thordardottir, S.; Fredrix, H.; Janssen, L.; Woestenenk, R.; Tel, J.; Joosten, B.; Cambi, A.; Heemskerk, M.H.M.; Franssen, G.M.; Boerman, O.C.; Bakker, L.B.H.; Jansen, J.H.; Schaap, N.; Dolstra, H. & Hobo, W. (2016), CLEC12A-Mediated Antigen Uptake and Cross-Presentation by Human Dendritic Cell Subsets Efficiently Boost Tumor-Reactive T Cell Responses, Journal of Immunology 197(7): 2715-2725.
- Hoang, T.P.; Foster, A.; Rodriguez, T.; Torres, D.; Lu, A.; Crisostomo, J.; Jahn, L.; Heemskerk, M.H.M. & Spencer, D.M. (2016), Go-TCR: Inducible MyD88/CD40 (iMC) Enhances Proliferation and Survival of Tumor-Specific TCR-Modified T Cells, Increasing Anti-Tumor Efficacy, Molecular Therapy 24: S294-S295.
- Spel, L.; Boelens, J.J.; Til, N. van; Steen, D.M. van der; Blokland, N.J.G.; Noesel, M.M. van; Molenaar, J.J.; Heemskerk, M.H.M.; Boes, M. & Nierkens, S. (2016), Improved CD8+T-cell recognition of neuroblastoma after innate immune attack by natural killer cells, Cancer Immunology Research 4(1).
- Jahn, L.; Hagedoorn, R.S.; Steen, D.M. van der; Hombrink, P.; Kester, M.G.D.; Schoonakker, M.P.; Ridder, D. de; Veelen, P.A. van; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2016), A CD22-reactive TCR from the T-cell allorepertoire for the treatment of acute lymphoblastic leukemia by TCR gene transfer, Oncotarget 7(44): 71536-71547.
- Flinsenberg, T.W.H.; Spel, L.; Jansen, M.; Koning, D.; Haar, C. de; Plantinga, M.; Scholman, R.; Loenen, M.M. van; Nierkens, S.; Boon, L.; Baarle, D. van; Heemskerk, M.H.M.; Boelens, J.J. & Boes, M. (2015), Cognate CD4 T-Cell Licensing of Dendritic Cells Heralds Anti-Cytomegalovirus CD8 T-Cell Immunity after Human Allogeneic Umbilical Cord Blood Transplantation, Journal of Virology 89(2): 1058-1069.
- Jahn, L.; Hagedoorn, R.S.; Hombrink, P.; Kester, M.G.D.; Steen, D.M. van der; Hassan, C.; Schoonakker, M.P.; Pijl, E. van der; Veelen, P.A. van; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2015), Cell Receptor Gene Therapy Targeting the Intracellular Transcription Factor Bob1 for the Treatment of Multiple Myeloma and Other B Cell Malignancies, Blood 126(23).
- Spel, L.; Boelens, J.J.; Steen, D.M. van der; Blokland, N.J.G.; Noesel, M.M. van; Molenaar, J.J.; Heemskerk, M.H.M.; Boes, M. & Nierkens, S. (2015), Natural killer cells facilitate PRAME-specific T-cell reactivity against neuroblastoma, Oncotarget 6(34): 35770-35781.
- Mare-Bredemeijer, E.L.D. de; Shi, X.L.; Mancham, S.; Gent, R. van; Heide-Mulder, M. van der; Boer, R. de; Heemskerk, M.H.M.; Jonge, J. de; Laan, L.J.W. van der; Metselaar, H.J. & Kwekkeboom, J. (2015), Cytomegalovirus-Induced Expression of CD244 after Liver Transplantation Is Associated with CD8(+) T Cell Hyporesponsiveness to Alloantigen, Journal of Immunology 195(4): 1838-1848.
- Hombrink, P.; Hassan, C.; Kester, M.G.D.; Jahn, L.; Pont, M.J.; Ru, A.H. de; Bergen, C.A.M. van; Griffioen, M.; Falkenburg, J.H.F.; Veelen, P.A. van & Heemskerk, M.H.M. (2015), Identification of Biological Relevant Minor Histocompatibility Antigens within the B-lymphocyte-Derived HLA-Ligandome Using a Reverse Immunology Approach, Clinical Cancer Research 21(9): 2177-2186.
- Hassan, C.; Chabrol, E.; Jahn, L.; Kester, M.G.D.; Ru, A.H. de; Drijfhout, J.W.; Rossjohn, J.; Falkenburg, J.H.F.; Heemskerk, M.H.M.; Gras, S. & Veelen, P.A. van (2015), Naturally Processed Non-canonical HLA-A*02:01 Presented Peptides, Journal of Biological Chemistry 290(5): 2593-2603.
- Jahn, L.; Hombrink, P.; Hassan, C.; Kester, M.G.D.; Steen, D.M. van der; Hagedoorn, R.S.; Falkenburg, J.H.F.; Veelen, P.A. van & Heemskerk, M.H.M. (2015), Therapeutic targeting of the BCR-associated protein CD79b in a TCR-based approach is hampered by aberrant expression of CD79b, Blood 125(6): 949-958.
- Jolink, H.; Boer, R. de; Willems, L.N.A.; Dissel, J.T. van; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2015), T helper 2 response in allergic bronchopulmonary aspergillosis is not driven by specific Aspergillus antigens, Allergy 70(10): 1336-1339.
- Frosig, T.M.; Yap, J.; Seremet, T.; Lyngaa, R.; Svane, I.M.; Straten, P.T.; Heemskerk, M.H.M.; Grotenbreg, G.M. & Hadrup, S.R. (2015), Design and Validation of Conditional Ligands for HLA-B*08:01, HLA-B*15:01, HLA-B*35:01, and HLA-B*44:05, Cytometry Part A 87A(10): 967-975.
- Flinsenberg, T.W.H.; Jansen, M.; Koning, D.; Baarle, D. van; Scholman, R.; Heemskerk, M.; Boelens, J.J. & Boes, M. (2015), Antigen-specific CD4(+) T cells are required for efficient crosspriming of human CMV-specific CD8(+) T cells in stem cell transplantation patients, Molecular Immunology 68(2): 137-138.
- Jahn, L.; Hombrink, P.; Hassan, C.; Kester, M.G.D.; Hagedoorn, R.S.; Steen, D.M. van der; Schoonakker, M.P.; Falkenburg, J.H.F.; Veelen, P.A. van & Heemskerk, M.H.M. (2014), High-Affinity CD20-Specific T-Cell Receptors Suitable for Adoptive Immunotherapy in the Treatment of CD20(low) B-Cell Malignancies, Blood 124(21).
- Breman, E.; Miert, P.P. van; Steen, D.M. van der; Heemskerk, M.H.; Doxiadis, I.I.; Roelen, D.; Claas, F.H. & Kooten, C. van (2014), HLA Monomers as a Tool to Monitor Indirect Allorecognition, Transplantation 97(11): 1119-1127.
- Jolink, H.; Hagedoorn, R.S.; Lagendijk, E.L.; Drijfhout, J.W.; Dissel, J.T. van; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2014), Induction of A. fumigatus-specific CD4-positive T cells in patients recovering from invasive aspergillosis.
- Pellicci, D.G.; Uldrich, A.P.; Nours, J. le; Ross, F.; Chabrol, E.; Eckle, S.B.G.; Boer, R. de; Lim, R.T.; McPherson, K.; Besra, G.; Howell, A.R.; Moretta, L.; McCluskey, J.; Heemskerk, M.H.M.; Gras, S.; Rossjohn, J. & Godfrey, D.I. (2014), The molecular bases of delta/alpha beta T cell-mediated antigen recognition, Journal of Experimental Medicine 211(13): 2599-2615.
- Jahn, L.; Hombrink, P.; Kester, M.G.D.; Schoonakker, M.P.; Falkenburg, J.F.; Veelen, P.A. van & Heemskerk, M.H.M. (2014), HIGH-AFFINITY CD20-SPECIFIC TCRS SUITABLE FOR ADOPTIVE IMMUNOTHERAPY CAN BE READILY ISOLATED FROM THE ALLO-REPERTOIRE USING REVERSE IMMUNOLOGY, Bone Marrow Transplantation 49: S17-S17.
- Loenen, M.M. van; Boer, R. de; Liempt, E. van; Meij, P.; Jedema, I.; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2014), A Good Manufacturing Practice procedure to engineer donor virus-specific T cells into potent anti-leukemic effector cells, Haematologica 99(4): 759-768.
- Jahn, L.; Hombrink, P.; Kester, M.G.D.; Steen, D.M. van der; Hagedoorn, R.S.; Hassan, C.; Schoonakker, M.P.; Pijl, E. van der; Veelen, P.A. van; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2014), T Cell Receptors Specific for the Intracellular Transcription Factor Bob1 Allow Efficient Targeting of Human B Cell Leukemia and Multiple Myeloma, Blood 124(21).
- Lugthart, G.; Ostaijen-ten Dam, M.M. van; Jol-van der Zijde, C.M.; Holten, T.C. van; Kester, M.G.D.; Heemskerk, M.H.M.; Bredius, R.G.M.; Toll, M.J.D. van & Lankester, A.C. (2014), Early Cytomegalovirus Reactivation Leaves a Specific and Dynamic Imprint on the Reconstituting T Cell Compartment Long-Term after Hematopoietic Stem Cell Transplantation, Biology of Blood and Marrow Transplantation 20(5): 655-661.
- Bonte, S.; Snauwaert, S.; Goetgeluk, G.; Heemskerk, M.; Stauss, H.; Vandekerckhove, B. & Kerre, T. (2014), FUNCTIONAL EVALUATION OF T-CELLS GENERATED FROM WT1-TCR TRANSDUCED HUMAN HEMATOPOIETIC STEM CELLS USING THE OP9-DL1 COCULTURE SYSTEM, Haematologica 99: 436-436.
- Jahn, L.; Hombrink, P.; Hassan, C.; Kester, M.G.D.; Hagedoorn, R.S.; Schoonakker, M.P.; Falkenburg, J.H.F.; Veelen, P.A. van & Heemskerk, M.H.M. (2014), High-affinity CD20-specific TCRs suitable for adoptive immunotherapy in the treatment of CD20low B cell malignancies, Human Gene Therapy 25(11): A92-A92.
- Heemskerk, M.H.M. (2014), High affinity T-cell receptors for targeting B-cell malignancies, Human Gene Therapy 25(11): A15-A15.
- Hassan, C.; Kester, M.G.D.; Oudgenoeg, G.; Ru, A.H. de; Janssen, G.M.C.; Drijfhout, J.W.; Spaapen, R.M.; Jimenez, C.R.; Heemskerk, M.H.M.; Falkenburg, J.H.F. & Veelen, P.A. van (2014), Accurate quantitation of MHC-bound peptides by application of isotopically labeled peptide MHC complexes, Journal of Proteomics 109: 240-244.
- Breman, E.; Miert, P.P. van; Steen, D.M. van der; Heemskerk, M.H.; Doxiadis, I.I.; Roelen, D.; Claas, F.H. & Kooten, C. van (2014), HLA monomers as a tool to monitor indirect allorecognition., Transplantation.
- Hassan, C.; Kester, M.G.D.; Ru, A.H. de; Hombrink, P.; Drijfhout, J.W.; Nijveen, H.; Leunissen, J.A.M.; Heemskerk, M.H.M.; Falkenburg, J.H.F. & Veelen, P.A. van (2013), The Human Leukocyte Antigen-presented Ligandome of B Lymphocytes, Molecular and Cellular Proteomics 12(7): 1829-1843.
- Heemskerk, M.H.M. (2013), Risks and benefits of alloreactivity, Immunology 140: 3-3.
- Loenen, M.M. van; Hagedoorn, R.S.; Boer, R. de; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2013), Extracellular Domains of CD8 alpha and CD8ss Subunits Are Sufficient for HLA Class I Restricted Helper Functions of TCR-Engineered CD4(+) T Cells, PLoS ONE 8(5).
- Linnemann, C.; Heemskerk, B.; Kvistborg, P.; Kluin, R.J.C.; Bolotin, D.A.; Chen, X.; Bresser, K.; Nieuwland, M.; Schotte, R.; Michels, S.; Gomez-Eerland, R.; Jahn, L.; Shu, C.J.; Kerkhoven, R.M.; Spits, H.; Hadrup, S.R.; Heemskerk, M.H.M.; Blankenstein, T.; Chudakov, D.M.; Bendle, G.M. & Schumacher, T.N.M. (2013), High-throughput isolation of antigen-specific T cell receptor genes by TCR gene capture, Human Gene Therapy 24(12): A31-A31.
- Hombrink, P.; Hassan, C.; Kester, M.G.D.; Ru, A.H. de; Bergen, C.A.M. van; Nijveen, H.; Drijfhout, J.W.; Falkenburg, J.H.F.; Heemskerk, M.H.M. & Veelen, P.A. van (2013), Discovery of T Cell Epitopes Implementing HLA-Peptidomics into a Reverse Immunology Approach, Journal of Immunology 190(8): 3869-3877.
- Loenen, M.M. van; Boer, R. de; Hagedoorn, R.S.; Jankipersadsing, V.; Amir, A.L.; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2013), Multi-cistronic vector encoding optimized safety switch for adoptive therapy with T-cell receptor-modified T cells, Gene Therapy 20(8): 861-867.
- Jolink, H.; Meijssen, I.C.; Hagedoorn, R.S.; Arentshorst, M.; Drijfhout, J.W.; Mulder, A.; Claas, F.H.J.; Dissel, J.T. van; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2013), Characterization of the T-Cell-Mediated Immune Response Against the Aspergillus fumigatus Proteins Crf1 and Catalase 1 in Healthy Individuals.
- Linnemann, C.; Heemskerk, B.; Kvistborg, P.; Kluin, R.J.C.; Bolotin, D.A.; Chen, X.J.; Bresser, K.; Nieuwland, M.; Schotte, R.; Michels, S.; Gomez-Eerland, R.; Jahn, L.; Hombrink, P.; Legrand, N.; Shu, C.J.; Mamedov, I.Z.; Velds, A.; Blank, C.U.; Haanen, J.B.A.G.; Turchaninova, M.A.; Kerkhoven, R.M.; Spits, H.; Hadrup, S.R.; Heemskerk, M.H.M.; Blankenstein, T.; Chudakov, D.M.; Bendle, G.M. & Schumacher, T.N.M. (2013), High-throughput identification of antigen-specific TCRs by TCR gene capture, Nature Medicine 19(11): 1534-+.
- Hombrink, P.; Raz, Y.; Kester, M.G.D.; Boer, R. de; Weissbrich, B.; Borne, P.A. von dem; Busch, D.H.; Schumacher, T.N.M.; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2013), Mixed functional characteristics correlating with TCR-ligand k(off)-rate of MHC-tetramer reactive T cells within the naive T-cell repertoire, European Journal of Immunology 43(11): 3038-3050.
- Coppernolle, S. van; Vanhee, S.; Verstichel, G.; Snauwaert, S.; Spek, A. van der; Velghe, I.; Sinnesael, M.; Heemskerk, M.H.; Taghon, T.; Leclercq, G.; Plum, J.; Langerak, A.W.; Kerre, T. & Vandekerckhove, B. (2012), Notch induces human T-cell receptor gamma delta plus thymocytes to differentiate along a parallel, highly proliferative and bipotent CD4 CD8 double-positive pathway, Leukemia 26(1): 127-138.
- Loenen, M.M. van; Boer, R. de; Liempt, P.A.G. van; Hagedoorn, R.S.; Meij, P.; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2012), A good manufacturing practice procedure to generate therapeutic numbers of highly pure anti-leukemic virus-specific T-cells, Immunology 137: 686-686.
- Jolink, H.; Hagedoorn, R.S.; Dissel, J.T. van; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2012), T cells specific for the Aspergillus proteins Crf1 and catalase1 develop in patients recovering from invasive aspergillosis, Immunology 137: 734-734.
- Loenen, M.M. van; Boer, R. de; Hagedoorn, R.S.; Jankipersadsing, V.; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2012), Multicistronic vector encoding optimized safety switch for adoptive therapy with TCR-modified T-cells, Immunology 137: 689-689.
- Amir, A.L.; Hagedoorn, R.S.; Luxemburg-Heijs, S.A.P. van; Marijt, E.W.A.; Kruisselbrink, A.B.; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2012), Identification of a Coordinated CD8 and CD4 T Cell Response Directed Against Mismatched HLA Class I Causing Severe Acute Graft-versus-Host Disease, Biology of Blood and Marrow Transplantation 18(2): 210-219.
- Jahn, L.; Hombrink, P.; Hassan, C.; Kester, M.G.D.; Falkenburg, J.H.F.; Veelen, P.A. van & Heemskerk, M.H.M. (2012), Two step selection protocol based on the expression of T cell activation marker CD137 increases efficacy in generating high-affinity allo-HLA restricted T cells, Immunology 137: 724-724.
- Van Coppernolle S, Vanhee S, Verstichel G, Snauwaert S, van der Spek A, Velghe I, Sinnegasael M, Heemskerk MH, Taghon T, Leclercq G, Plum J, Langerak AW, Kerre T & Vandekerckhove B. (2012), Notch induces human T cell receptor gammadelta+ thymocytes to differentiate along a parallel, high proliferative and bipotent CD4 CD8 double-positive pathway, Leukemia.
- Spranger, S.; Jeremias, I.; Wilde, S.; Leisegang, M.; Starck, L.; Mosetter, B.; Uckert, W.; Heemskerk, M.H.M.; Schendel, D.J. & Frankenberger, B. (2012), TCR-transgenic lymphocytes specific for HMMR/Rhamm limit tumor outgrowth in vivo, Blood.
- Hombrink, P.; Hassan, C.; Kester, M.G.D.; Bergen, C.A.M. van; Falkenburg, J.H.F.; Veelen, P.A. van & Heemskerk, M.H.M. (2011), HLA-Peptidomics and the Identification of Clinical Relevant Minor Histocompatibility Antigens, Blood 118(21): 1725-1725.
- Hombrink, P.; Hadrup, S.R.; Bakker, A.; Kester, M.G.D.; Falkenburg, J.H.F.; Borne, P.A.V.; Schumacher, T.N.M. & Heemskerk, M.H.M. (2011), High-Throughput Identification of Potential Minor Histocompatibility Antigens by MHC Tetramer-Based Screening: Feasibility and Limitations, PLoS ONE 6(8).
- Thomas, S.; Klobuch, S.; Plachter, B.; Heemskerk, M.; Theobald, M. & Herr, W. (2011), Memory T-cells of CMV-negative donors are superior recipients of CMV-specific T-cell receptor RNA, Bone Marrow Transplantation 46: S313-S314.
- Falkenburg, W.J.J.; Melenhorst, J.J.; Meent, M. van de; Kester, M.G.D.; Hombrink, P.; Heemskerk, M.H.M.; Hagedoorn, R.S.; Gostick, E.; Price, D.A.; Falkenburg, J.H.F.; Barrett, A.J. & Jedema, I. (2011), Allogeneic HLA-A*02-Restricted WT1-Specific T Cells from Mismatched Donors Are Highly Reactive but Show Off-Target Promiscuity, Journal of Immunology 187(5): 2824-2833.
- Amir, A.L.; Steen, D.M. van der; Hagedoorn, R.S.; Kester, M.G.D.; Bergen, C.A.M. van; Drijfhout, J.W.; Ru, A.H. de; Falkenburg, J.H.F.; Veelen, P.A. van & Heemskerk, M.H.M. (2011), Allo-HLA-reactive T cells inducing graft-versus-host disease are single peptide specific, Blood 118(26): 6733-6742.
- Scholten, K.B.J.; Turksma, A.W.; Ruizendaal, J.J.; Hende, M. van den; Burg, S.H. van der; Heemskerk, M.H.M.; Meijer, C.J.L.M. & Hooijberg, E. (2011), Generating HPV specific T helper cells for the treatment of HPV induced malignancies using TCR gene transfer, Journal of Translational Medicine 9.
- Amir, A.L.; Steen, D.M. van der; Loenen, M.M. van; Hagedoorn, R.S.; Boer, R. de; Kester, M.D.G.; Ru, A.H. de; Lugthart, G.J.; Kooten, C. van; Hiemstra, P.S.; Jedema, I.; Griffioen, M.; Veelen, P.A. van; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2011), PRAME-Specific Allo-HLA-Restricted T Cells with Potent Antitumor Reactivity Useful for Therapeutic T-Cell Receptor Gene Transfer, Clinical Cancer Research 17(17): 5615-5625.
- Loenen, M.M. van; Boer, R. de; Hagedoorn, R.S.; Egmond, E.H.M. van; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2011), Optimization of the HA-1-specific T-cell receptor for gene therapy of hematologic malignancies, Haematologica 96(3): 477-481.
- Loenen, M.M. van; Hagedoorn, R.S.; Boer, R. de; Egmond, E.H.M. van; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2011), Rapid Re-expression of Retrovirally Introduced Versus Endogenous TCRs in Engineered T cells After Antigen-specific Stimulation, Journal of Immunotherapy 34(2): 163-172.
- Jolink, H.; Oorschot, E. van; Kuijper, E.J.; Drijfhout, J.W.; Dissel, J.T.; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2010), Identification of Multiple HLA Class II Epitopes of Aspergillus Fumigatus by Generation of CD4+T Cell Clones Recognizing the A. Fumigatus proteins Crf1 and Catalase1., Blood 116(21): 963-963.
- Amir, A.L.; D'Orsogna, L.J.A.; Roelen, D.L.; Loenen, M.M. van; Hagedoorn, R.S.; Boer, R. de; Hoorn, M.A.W.G. van der; Kester, M.G.D.; Doxiadis, I.I.N.; Falkenburg, J.H.F.; Claas, F.H.J. & Heemskerk, M.H.M. (2010), Allo-HLA reactivity of virus-specific memory T cells is common, Blood 115(15): 3146-3157.
- Raz, Y.; Hombrink, P.; Borne, P.A. von dem; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2010), Pull down and expansion of naive CMV-specific T-cells covering multiple HLA class I alleles, European Journal of Medical Research 15: 99-100.
- Thomas, S.; Klobuch, S.; Besold, K.; Plachter, B.; Heemskerk, M.H.M.; Schaft, N.; Voss, R.H.; Theobald, M. & Herr, W. (2010), Reprogramming T cells of CMV-negative donors with CMV-specific T cell receptor RNA, Onkologie 33: 98-98.
- Loenen, M.M. van; Boer, R. de; Hagedoorn, R.S.; Egmond, H.M. van; Amir, A.L.; Willemze, R.; Falkenburg, J.H.F. & Heemskerk, M. (2010), Optimization of the HA-1-specific T-cell receptor for gene therapy of haematological malignancies after stem cell transplantation, Bone Marrow Transplantation 45: S65S65.
- Loenen, M.M. van; Boer, R. de; Amir, A.L.; Hagedoorn, R.S.; Volbeda, G.L.; Willemze, R.; Rood, J.J. van; Falkenburg, J.H.F. & Heemskerk, M.H.M. (2010), Mixed T cell receptor dimers harbor potentially harmful neoreactivity, Proceedings of the National Academy of Sciences 107(24): 10972-10977.
- Heemskerk, M.H.M. (2010), T-cell receptor gene transfer for the treatment of leukemia and other tumors, Haematologica 95(1): 15-19.
- Zhang, Y.; Liu, Y.Y.; Moxley, K.M.; Golden-Mason, L.; Hughes, M.G.; Liu, T.X.; Heemskerk, M.H.M.; Rosen, H.R. & Nishimura, M.I. (2010), Transduction of Human T Cells with a Novel T-Cell Receptor Confers Anti-HCV Reactivity, PLoS Pathogens 6(7).
- Dorsogna L, Amir A, Zoet Y, van Miert P, van der Meer-Prins E, Kester M, Falkenburg F, Heemskerk M, Doxiadis I & Roelen D (2009), New tools to monitor the impact of viral infection on the alloreactive T-cell repertoire, Tissue Antigens 73(5): 387-387.
- D'Orsogna L, Amir A, Zoet Y, van Miert P, van der Meer-Prins E, Kester M, Falkenburg F, Heemskerk M, Doxiadis I & Roelen D (2009), New Tools To Monitor the Impact of Viral Infection on the Alloreactive T-Cell Repertoire., American Journal of Transplantation 9: 478-478.
- Thomas S, Klobuch S, Heemskerk MHM, Stolle D, Besold K, Plachter B, Schaft N, Theobald M, Voss RH & Herr W (2009), Generation of CMV Specific T Cells From CMV Seronegative Donors by T Cell Receptor RNA Transfer., Blood 114(22): 1386-1386.
- van Loenen MM, Hagedoorn RS, de Boer R, van Egmond EM, Willemze R, Falkenburg JHF & Heemskerk MHM (2009), Optimization of the HA-1-Specific T Cell Receptor for Gene Therapy of Hematological Malignancies., Blood 114(22): 1570-1570.
- Amir AL, van der Steen DM, Hagedoorn RS, Griffioen M, Falkenburg JHF & Heemskerk MHM (2009), High Avidity PRAME Specific T Cells Derived From In Vivo HLA Mismatched Transplantation Setting Potentially Useful for Immunotherapeutic Strategies., Blood 114(22): 1568-1568.
- van Loenen MM, Hagedoorn RS, Willemze R, Falkenburg JHF & Heemskerk MHM (2009), Extracellular Domains of CD8a and beta Subunits Are Required and Sufficient for HLA Class I Restricted Helper Activity of TCR-Engineered CD4(+) T Cells., Blood 114(22): 1385-1385.
- Hadrup SR, Bakker AH, Shu CYJ, Andersen RS, van Veluw J, Hombrink P, Castermans E, Straten PT, Blank C, Haanen JB, Heemskerk MH & Schumacher TN (2009), Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers, Nature Methods 6(7): 520U79.
- Pfistershammer K, Lawitschka A, Klauser C, Leitner J, Weigl R, Heemskerk MHM, Pickl WF, Majdic O, Bohmig GA, Fischer GF, Greinix HT & Steinberger P (2009), Allogeneic disparities in immunoglobulin-like transcript 5 induce potent antibody responses in hematopoietic stem cell transplant recipients, Blood 114(11): 2323-2332.
- Griffioen M, van Egmond EHM, Kester MGD, Willemze R, Falkenburg JHF & Heemskerk MHM (2009), Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy, Haematologica 94(9): 1316-1320.
- van Loenen MM, Hagedoorn RS, Kester NGD, Hoogeboom M, Willemze R, Falkenburg JHF & Heemskerk MHM (2009), Kinetic Preservation of Dual Specificity of Coprogrammed Minor Histocompatibility Antigen-Reactive Virus-Specific T Cells, Cancer Research 69(5): 2034-2041.
- Falkenburg WJJ, Melenhorst JJ, Kester MGD, Hombrink P, Heemskerk MHM, Gostick E, Price DA, Falkenburg JHF, Barrett AJ & Jedema I (2009), Allogeneic HLA-A2-Restricted WT1-Specific T Cells From Mismatched Donors Are Highly Reactive but Show Potentially Hazardous Promiscuity, Blood 114(22): 1565-1565.
- van der Heiden PLJ, de Boer R, van der Steen DM, Kester MGD, van der Hoorn MWAG, Haarman WME, Barnby-Porritt HE, Fry JW, Napper CE, Marijt EWA, Willemze R, Falkenburg JHF & Heemskerk MHM (2009), Identification of Varicella-Zoster Virus-Specific CD8 T Cells in Patients after T-Cell-Depleted Allogeneic Stem Cell Transplantation, Journal of Virology 83(14): 7361-7364.
- van der Veken LT, Campelo MD, van der Hoorn MAWG, Hagedoorn RS, van Egmond HME, van Bergen J, Willemze R, Falkenburg JHF & Heemskerk MHM (2009), Functional Analysis of Killer Ig-Like Receptor-Expressing Cytomegalovirus-Specific CD8(+) T Cells, Journal of Immunology 182(1): 92-101.
- van der Veken LT, Coccoris M, Swart E, Falkenburg JHF, Schumacher TN & Heemskerk MHM (2009), alpha beta T Cell Receptor Transfer to gamma delta T Cells Generates Functional Effector Cells without Mixed TCR Dimers In Vivo, Journal of Immunology 182(1): 164-170.
- D'Orsogna LJ, Amir AL, Zoet YM, Meer-Prins PMWD, Slik ARD, Kester MGD, Heemskerk MHM, Doxiadis IIN, Roelen DL & Claas FHJ (2009), New tools to monitor the impact of viral infection on the alloreactive T-cell repertoire, Tissue Antigens 74(4): 290-297.
- Amir AL, D'Orsogna LJ, van Loenen MM, Kester M, Roelen DL, Doxiadis II, Falkenburg F, Heemskerk M & Claas FH (2009), Alloreactivity of Virus Specific Memory T-Cells., American Journal of Transplantation 9: 361-361.
- Amir A, Dorsogna L, van Loenen M, Kester M, Doxiadis I, Roelen D, Falkenburg F, Heemskerk M & Claas F (2009), Alloreactivity of virus specific memory T-cells is common, Tissue Antigens 73(5): 385-385.
- Hombrink P, Hadrup SR, Bakker A, Falkenburg JHF, Borne PAVD, Schumacher TN & Heemskerk MHM (2008), SNP-Based Genome-Wide Identification of Hematopoiesis-Restricted Minor Histocompatibility Antigens, Blood 112(11): 302-302.
- Loenen MM, Boer R, Volbeda GL, Amir AL, Hagedoorn RS, Willemze R, Falkenburg JHF & Heemskerk MHM (2008), Recombination of Endogenous TCR Chains with Retrovirally Introduced TCR Chains Can Result in Mixed T Cell Receptor Dimers Harbouring Harmful Alloreactivity, Blood 112(11): 305-305.
- Rutten CE, van Luxemburg-Heijs SAP, Griffioen M, Marijt WAE, Jedema I, Heemskerk MHM, Posthuma FM, Willemze R & Falkenburg JH (2008), HLA-DP AS SPECIFIC TARGET FOR GRAFT VERSUS LEUKEMIA REACTIVITY IN HLA-CLASS II EXPRESSING HEMATOLOGICAL MALIGNANCIES, Haematologica 93: 351-352.
- Amir AL, D'Orsogna LJA, van Loenen MM, Roelen DL, Doxiadis IIN, Claas FHJ, Falkenburg JHF & Heemskerk MHM (2008), Alloreactivity of Virus Specific T-Cells, Blood 112(11): 1116-1116.
- van Loenen MM, Griffioen M, van Egmond HME, Hagedoorn RS, Kester M, Willemze R, Falkenburg JHF & Heemskerk MHM (2008), T CELL RECEPTOR GENE TRANSFER TO VIRUS-SPECIFIC T CELLS FOR CELLULAR ANTI-TUMOR IMMUNOTHERAPY, Biology of Blood and Marrow Transplantation 14(2): 124-124.
- Jedema I, van Dreunen L, van Loenen MM, Heemskerk MHM, Willerrize R & Falkenburg JHF (2008), VIGOROUS PRIMING OF MINOR HISTOCOMPATIBILITY ANTIGEN SPECIFIC T CELLS BY FREQUENT HIGH DOSE PEPTIDE VACCINATION MAY LEAD TO PROLONGED T CELL RECEPTOR DOWNREGULATION, IMPAIRED T CELL FUNCTIONALITY, AND PROMOTION OF TUMOR ESCAPE, Haematologica 93: 239-240.
- Bakker AH, Hoppes R, Linnemann C, Toebes M, Rodenko B, Berkers CR, Hadrup SR, van Esch WJE, Heemskerk MHM, Ovaa H & Schumacher TNM (2008), Conditional MHC class I ligands and peptide exchange technology for the human MHC gene products HLA-A1, -A3, -A11 and -B7, Proceedings of the National Academy of Sciences 105(10).